246 related articles for article (PubMed ID: 36993818)
1. Dopamine receptor agonists mechanism of actions on glucose lowering and their connections with prolactin actions.
Chien HY; Chen SM; Li WC
Front Clin Diabetes Healthc; 2023; 4():935872. PubMed ID: 36993818
[TBL] [Abstract][Full Text] [Related]
2. Central prolactin modulates insulin sensitivity and insulin secretion in diabetic rats.
Park S; Kang S; Lee HW; Ko BS
Neuroendocrinology; 2012; 95(4):332-43. PubMed ID: 22441304
[TBL] [Abstract][Full Text] [Related]
3. Dopamine D2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic profile in type 2 diabetes.
Tavares G; Marques D; Barra C; Rosendo-Silva D; Costa A; Rodrigues T; Gasparini P; Melo BF; Sacramento JF; Seiça R; Conde SV; Matafome P
Mol Metab; 2021 Sep; 51():101241. PubMed ID: 33933677
[TBL] [Abstract][Full Text] [Related]
4. Metabolic effects of prolactin.
Pirchio R; Graziadio C; Colao A; Pivonello R; Auriemma RS
Front Endocrinol (Lausanne); 2022; 13():1015520. PubMed ID: 36237192
[TBL] [Abstract][Full Text] [Related]
5. Dopaminergic drugs in type 2 diabetes and glucose homeostasis.
Lopez Vicchi F; Luque GM; Brie B; Nogueira JP; Garcia Tornadu I; Becu-Villalobos D
Pharmacol Res; 2016 Jul; 109():74-80. PubMed ID: 26748034
[TBL] [Abstract][Full Text] [Related]
6. Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels.
Krysiak R; Okopien B
Basic Clin Pharmacol Toxicol; 2015 Mar; 116(3):251-6. PubMed ID: 25123447
[TBL] [Abstract][Full Text] [Related]
7. Suppression of Prolactin Secretion Partially Explains the Antidiabetic Effect of Bromocriptine in ob/ob Mice.
Furigo IC; Suzuki MF; Oliveira JE; Ramos-Lobo AM; Teixeira PDS; Pedroso JA; de Alencar A; Zampieri TT; Buonfiglio DC; Quaresma PGF; Prada PO; Bartolini P; Soares CRJ; Donato J
Endocrinology; 2019 Jan; 160(1):193-204. PubMed ID: 30462197
[TBL] [Abstract][Full Text] [Related]
8. Glucose Abnormalities Associated to Prolactin Secreting Pituitary Adenomas.
Auriemma RS; De Alcubierre D; Pirchio R; Pivonello R; Colao A
Front Endocrinol (Lausanne); 2019; 10():327. PubMed ID: 31191454
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
10. Rapid and dramatic glucose-lowering effect of bromocriptine in an inadequately controlled type 2 diabetes patient with prolactinoma.
Igata M; Yagi Y; Hanatani S; Sakaguchi M; Ishii N; Yoshinaga K; Kawashima J; Motoshima H; Araki E
J Diabetes Investig; 2021 Apr; 12(4):668-671. PubMed ID: 32706496
[TBL] [Abstract][Full Text] [Related]
11. Change in Insulin Sensitivity and Lipid Profile After Dopamine Agonist Therapy in Patients With Prolactinoma.
Khalil G; Khan FA; Jamal QM; Saleem A; Masroor H; Abbas K
Cureus; 2021 Sep; 13(9):e17824. PubMed ID: 34660034
[TBL] [Abstract][Full Text] [Related]
12. Effects of Pituitary Surgery and High-Dose Cabergoline Therapy on Metabolic Profile in Patients With Prolactinoma Resistant to Conventional Cabergoline Treatment.
Pirchio R; Auriemma RS; Solari D; Arnesi M; Pivonello C; Negri M; de Angelis C; Cavallo LM; Cappabianca P; Colao A; Pivonello R
Front Endocrinol (Lausanne); 2021; 12():769744. PubMed ID: 34917030
[TBL] [Abstract][Full Text] [Related]
13. Bromocriptine improves glucose tolerance independent of circadian timing, prolactin, or the melanocortin-4 receptor.
Framnes-DeBoer SN; Bakke E; Yalamanchili S; Peterson H; Sandoval DA; Seeley RJ; Arble DM
Am J Physiol Endocrinol Metab; 2020 Jan; 318(1):E62-E71. PubMed ID: 31794265
[TBL] [Abstract][Full Text] [Related]
14. Macroprolactinoma with secondary resistance to dopamine agonists: a case report and review of the literature.
Tng EL; Teo AE; Aung AT
J Med Case Rep; 2023 Mar; 17(1):96. PubMed ID: 36927797
[TBL] [Abstract][Full Text] [Related]
15. Age-dependent association of serum prolactin with glycaemia and insulin sensitivity in humans.
Wagner R; Heni M; Linder K; Ketterer C; Peter A; Böhm A; Hatziagelaki E; Stefan N; Staiger H; Häring HU; Fritsche A
Acta Diabetol; 2014 Feb; 51(1):71-8. PubMed ID: 23836327
[TBL] [Abstract][Full Text] [Related]
16. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy.
Berinder K; Nyström T; Höybye C; Hall K; Hulting AL
Pituitary; 2011 Sep; 14(3):199-207. PubMed ID: 21128120
[TBL] [Abstract][Full Text] [Related]
17. Prolactin-lowering and -releasing drugs. Mechanisms of action and therapeutic applications.
Müller EE; Locatelli V; Cella S; Peñalva A; Novelli A; Cocchi D
Drugs; 1983 Apr; 25(4):399-432. PubMed ID: 6133737
[TBL] [Abstract][Full Text] [Related]
18. Effects of dopamine d2 receptor agonists in a pituitary transplantation-induced hyperprolactinaemia/anovulation model in rats.
Moro M; Inada Y; Miyata H; Komatsu H; Kojima M; Tsujii H
Clin Exp Pharmacol Physiol; 2001 Aug; 28(8):651-8. PubMed ID: 11473532
[TBL] [Abstract][Full Text] [Related]
19. Disruption of the dopamine d2 receptor impairs insulin secretion and causes glucose intolerance.
García-Tornadú I; Ornstein AM; Chamson-Reig A; Wheeler MB; Hill DJ; Arany E; Rubinstein M; Becu-Villalobos D
Endocrinology; 2010 Apr; 151(4):1441-50. PubMed ID: 20147524
[TBL] [Abstract][Full Text] [Related]
20. Alternative Treatment Strategies in Women Poorly Tolerating Moderate Doses of Bromocriptine.
Krysiak R; Szkróbka W; Okopień B
Exp Clin Endocrinol Diabetes; 2017 Jun; 125(6):360-364. PubMed ID: 28073129
[No Abstract] [Full Text] [Related]
[Next] [New Search]
